Jung-joo Choi

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Antitumor efficacy of repurposed phenformin in preclinical models of epithelial ovarian cancer.

Antitumor efficacy of repurposed phenformin in preclinical models of epithelial ovarian cancer.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 04, 2026

Time-Resolved Transcriptomic Profiling of Surgical Wounds Identifies Stage-Specific Therapeutic Targets for Residual Ovarian Cancer.

Time-Resolved Transcriptomic Profiling of Surgical Wounds Identifies Stage-Specific Therapeutic Targets for Residual Ovarian Cancer.

Journal: Pharmaceutics

Published: February 02, 2026

Systematic growth factor profiling platform for 3D tumor models reveals estradiol-responsive cellular mechanisms of immunotherapy resistance.

Systematic growth factor profiling platform for 3D tumor models reveals estradiol-responsive cellular mechanisms of immunotherapy resistance.

Journal: Biofabrication

Published: July 16, 2025

Temperature-Controlled pNIB/PTX Micelles for Improved Paclitaxel Delivery in Ovarian Cancer Treatment.

Temperature-Controlled pNIB/PTX Micelles for Improved Paclitaxel Delivery in Ovarian Cancer Treatment.

Journal: ACS biomaterials science & engineering

Published: March 17, 2025

Anticancer Effects of BAF312 (Siponimod) in Epithelial Ovarian Cancer.

Anticancer Effects of BAF312 (Siponimod) in Epithelial Ovarian Cancer.

Journal: Anticancer research

Published: June 26, 2024

Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer.

Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer.

Journal: Gynecologic oncology

Published: April 23, 2024

Anticancer effect of the antipsychotic agent penfluridol on epithelial ovarian cancer.

Anticancer effect of the antipsychotic agent penfluridol on epithelial ovarian cancer.

Journal: Journal of gynecologic oncology

Published: April 22, 2024

Ulipristal acetate, a selective progesterone receptor modulator, induces cell death via inhibition of STAT3/CCL2 signaling pathway in uterine sarcoma.

Ulipristal acetate, a selective progesterone receptor modulator, induces cell death via inhibition of STAT3/CCL2 signaling pathway in uterine sarcoma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: September 05, 2023

The anti-tumor effects of AZD4547 on ovarian cancer cells: differential responses based on c-Met and FGF19/FGFR4 expression.

The anti-tumor effects of AZD4547 on ovarian cancer cells: differential responses based on c-Met and FGF19/FGFR4 expression.

Journal: Cancer cell international

Published: August 23, 2023

High-throughput organo-on-pillar (high-TOP) array system for three-dimensional ex vivo drug testing.

High-throughput organo-on-pillar (high-TOP) array system for three-dimensional ex vivo drug testing.

Journal: Biomaterials

Published: December 12, 2022

Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer.

Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer.

Journal: Journal of gynecologic oncology

Published: October 06, 2022

Changes in subcellular localization of Lysyl-tRNA synthetase and the 67-kDa laminin receptor in epithelial ovarian cancer metastases.

Changes in subcellular localization of Lysyl-tRNA synthetase and the 67-kDa laminin receptor in epithelial ovarian cancer metastases.

Journal: Cancer biomarkers : section A of Disease markers

Published: August 01, 2022

Showing 1-12 of 38

Last Updated: 09/26/2026